Search research articles
Contact Us
Filters
Showing results (91-100 of 126) with videos related to
Page
of 13
Sort By:
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association
|
July 10, 2012
In vitro and in vivo activity of gallic acid and Toona sinensis leaf extracts against HL-60 human premyelocytic leukemia
Pei-Jane Huang, You-Cheng Hseu, Meng-Shiou Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
British Journal of Haematology
|
December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull, Jan A Burger, Stephen Opat, et al.
Leukemia
|
September 15, 2019
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song, Quanli Gao, Huilai Zhang, et al.
Blood Advances
|
October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S Tam, Hang Quach, Andrew Nicol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 29, 2020
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
Blood
|
July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Judith Trotman, Stephen Opat, David Gottlieb, et al.
British Journal of Haematology
|
March 19, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas
Jacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, et al.
Blood
|
March 18, 2022
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 126) with videos related to
Sort By:
Page
of 13
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association
|
July 10, 2012
In vitro and in vivo activity of gallic acid and Toona sinensis leaf extracts against HL-60 human premyelocytic leukemia
Pei-Jane Huang, You-Cheng Hseu, Meng-Shiou Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
British Journal of Haematology
|
December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull, Jan A Burger, Stephen Opat, et al.
Leukemia
|
September 15, 2019
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song, Quanli Gao, Huilai Zhang, et al.
Blood Advances
|
October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S Tam, Hang Quach, Andrew Nicol, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 29, 2020
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
Blood
|
July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Judith Trotman, Stephen Opat, David Gottlieb, et al.
British Journal of Haematology
|
March 19, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas
Jacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, et al.
Blood
|
March 18, 2022
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song, Keshu Zhou, Dehui Zou, et al.
Page
of 13